Sonia T. Oskouei, PharmD, vice president of innovation and solution development at Premier Inc, discusses how biosimilars have impacted innovation in oncology.
Transcript
So biosimilars really have had a significant impact at innovation in general, including oncology. And so here's my perspective: I think it not only represents innovation but it also fosters innovation.
So biosimilars, the regulatory pathway, the Biologics Price Competition and Innovation Act, innovation’s in the name, was really innovative to create an expedited pathway to bring these life-saving biologic therapies to market sooner. So not only was the regulatory pathway innovative with creating the concept of extrapolation and relying on the totality of evidence to be able to do so, but also the manufacturing process for these biosimilars represent innovation.
The technology and the ability to develop these biologics have come a long way even since the originator biologics were First developed. Now the way that biosimilars have fostered innovation and continue to do so, we could see it even from the originator biologics, we could see enhanced formulations or even dosage form. So, biologics that were traditionally infused are now available [subcutaneously] to other areas that we see it fostering innovation is even in the health system setting.
Creating these biosimilar strategies and processes from a health system perspective has really catapulted the development of a true education program within health systems to ease the transition to a biosimilar or start a new biosimilar for a new patient. A lot of time that's that goes with educating nurses, physicians, pharmacists, really a multi-stakeholder approach, and really keeping the pressure patient at the forefront of it.
Being able to create the process where patients are notified, educated on what these products are, why it's okay to be switching, and the potential impact it could have on out-of-pocket costs and the finance is really important, and that's represented innovation from a process standpoint within health systems too.
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
PBM Evolution Toward Value-Based Care Shifts to Transparent Pharmacy Pricing
March 30th 2025Josh Canavan, PharmD, RazorMetrics, and Chris O'Dell, Turquoise Health, predict pharmacy benefit managers (PBMs) will evolve toward value-based care, mirroring the broader shift toward open-cost structures.